Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial

Annals of Oncology

Volumn 7, Issue 8, 1996, Pages 821-826

  Gridelli, C ^a   Perrone, F ^a,b   Palmeri, S ^c   D'Aprile, M ^d   Cognetti, F ^e   Rossi, A ^f   Gebbia, V ^c   Pepe, R ^f   Veltri, E ^d   Airoma, G ^f   Russo, A ^c   Incoronato, P ^f   Scinto, A F ^c   Palazzolo, G ^f   Natali, M ^d   Leonardi, V ^c   Gallo, C ^b   De Placido, S ^b,f   Bianco, A R ^f  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d SANTA MARIA GORETTI HOSPITAL   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Chemotherapy; Non cisplatin containing regimen; Stage IV NSCLC

Indexed keywords

CISPLATIN; DEXAMETHASONE; ETOPOSIDE; METOCLOPRAMIDE; MITOMYCIN C; ONDANSETRON; VINDESINE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

EID: 10244246636     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010761     Document Type: Article

References (20)

1. Kris MG, Gralla RJ, Wertheim MS et al. Trial of the combination of mitomycin, vindesine and cisplatin in patients with advanced non-small-cell lung cancer. Cancer Treat Rep 1986; 70: 1091-6.
2. Giaccone G, Bagatella M, Donadio M et al. Mitomycin C, vinblastine and cisplatin. An active regimen for advanced non-small-cell lung cancer. Br J Cancer 1987; 56: 475-8.
3. Kris MG, Gralla RJ, Kalman LA et al. Randomised trial comparing vindesine plus cisplatin in patients with non-small-cell lung cancer with an analysis of methods of response assessment. Cancer Treat Rep 1985; 69: 387-95.
4. Luedke DW, Luedke SL, Martelo O et al. Vindesine and mitomycin in the treatment of advanced non-small-cell lung cancer: A Southern Cancer Group Trial. Cancer Treat Rep 1986; 70: 651-3.
5. Sculier JP, Klastersky J, Dumont JP et al. Combination chemotherapy with mitomycin and vindesine in advanced non-small-cell lung cancer: A pilot study by the Lung Cancer Working Party (Belgium). Cancer Treat Rep 1986; 70: 773-5.
6. Shinkai T, Sajio N, Tominaga K et al. Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small-cell lung cancer. Cancer Treat Rep 1985; 69: 945-51.
7. Luedke DW, Einhorn L, Omura GA et al. Randomized comparison of two combination regimens versus minimal chemotherapy in non-small-cell lung cancer: A Southern Cancer Study Group Trial. J Clin Oncol 1990; 8: 886-91.
8. Gatzemeier U, Heckmayr M, Hossfeld DK et al. A randomized trial with mitomycin C/ifosfamide vs. mitomycin C/vindesine vs. cisplatin/etoposide in advanced non-small-cell lung cancer. Am J Clin Oncol 1991; 14: 405-11.
9. Itri L, Gralla RJ. A review of etoposide in patients with non-small-cell lung cancer (NSCLC). Cancer Treat Rev 1982; 9: 115-8.
10. Gridelli C, Pepe R, Palmeri S et al. Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer. Cancer Chemother Pharmacol 1991; 28: 405-7.
11. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
12. Kaplan EL, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-81.
13. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep 1966; 50: 163-70.
14. Cox DR. Regression models and life tables. J R Stat Soc 1972; B34: 187-220.
15. Non Small Cell Lung Cancer Cooperative Group. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
16. Shinkai T, Eguchi K, Sasaki Y et al. A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small-cell lung cancer. Eur J Cancer 1991; 27: 571-5.
17. Gonzales-Baron M, Felin J, Espinosa E et al. Comparison of two chemotherapeutic regimens - mitomycin + vindesine + cisplatin (MVP) vs. mitomycin + ifosfamide + cisplatin (MIP) in advanced non-small-cell lung cancer. Ann Oncol 1994; 5: 323-7.
18. Crinò L, Clerici M, Figoli F et al. Chemotherapy of advanced non-small-cell lung cancer: A comparison of three active regimen. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann Oncol 1995; 6: 347-53.
19. Le Chevalier T, Brisgand D, Donilland J et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicentre trial including 612 patients. J Clin Oncol 1994; 12: 360-7.
20. Crinò L, Scagliotti G, Marangolo M et al. Cisplatin-gemcitabine combination in non-small-cell lung cancer (NSCLC). A phase II study. Proc Am Soc Clin Oncol 1995; 14: 352 (Abstr).